Prolonged Exposure Therapy for Combat- and Terror-Related Posttraumatic Stress Disorder: A Randomized Control Comparison With Treatment as Usual

Nitzah Nacasch, MD; Edna B. Foa, PhD; Jonathan D. Huppert, PhD; Dana Tzur, MA; Leah Fostick, PhD; Yula Dinstein, MA; Michael Polliack, MD; and Joseph Zohar, MD

Published: November 16, 2010

Article Abstract

Objective: Empirically based studies have demonstrated that prolonged exposure therapy effectively reduces posttraumatic stress disorder (PTSD) symptoms in a vast range of traumas, yet reports of the efficacy of such therapies in combat- and terror-related PTSD are scarce. In this article, we examine the efficacy of prolonged exposure therapy in combat- and terror-related PTSD in comparison to treatment as usual (TAU).

Method: Between July 2002 and October 2005, 30 patients of a trauma unit within a psychiatric outpatient clinic were recruited and randomized into prolonged exposure versus TAU therapies. Patients were diagnosed with chronic PTSD (Mini-International Neuropsychiatric Interview criteria) related to combat- (n = 19) or terror-related (n = 11) trauma. Main outcome measures included symptoms of PTSD and depression, as measured by the PTSD Symptom Scale-Interview Version and the Beck Depression Inventory.

Results: Posttraumatic stress disorder symptom severity was significantly lower in patients who received prolonged exposure therapy in comparison to patients who received TAU (F1,24 = 35.3, P < .001). Similar results have emerged in measures of depression and state and trait anxiety. In addition, a significant change from pretreatment to follow-up was found for the prolonged exposure group (F1,14 = 80.5, P < .0001), but not for the TAU group (F1,10.3 = 0.6, P = .44).

Conclusions: Findings indicate that, similar to PTSD related to other types of trauma, prolonged exposure therapy is beneficial in the amelioration of combat- and terror-related PTSD symptoms. In addition, prolonged exposure was superior to TAU in the short- and long-term reduction of PTSD and depression symptoms.

Trial Registration: Identifier: NCT00229372

J Clin Psychiatry

Submitted: August 25, 2009; accepted January 18, 2010.

Online ahead of print: November 16, 2010 (doi:10.4088/JCP.09m05682blu).

Corresponding author: Edna B. Foa, PhD, University of Pennsylvania Department of Psychiatry, Center for the Treatment and Study of Anxiety, 3535 Market St, 6th Fl, Philadelphia, PA 19104 (

Volume: 71

Quick Links: PTSD , Trauma

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF


Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...